A pseudorabies virus (Becker strain) glycoprotein gene was located in the UL region at map position 0.40. (1, 14) and a secreted glycoprotein (1, 25) are synthesized. The structural glycoproteins are found embedded in the nuclear and cellular membranes of infected cells as well as on the surface of the mnature, enveloped virions. These PRV glycoproteins play a pivotal role in the life cycle of the virus and are likely to be the major antigens that interact with the host immune system eliciting both humoral and cell-mediated immune responses (reviewed in references 9, 23, 28) .
In general, the role of individual PRV glycoproteins in the virus life cycle or in viral pathogenicity is poorly understood. Only recently have genome locations of PRV-encoded glycoproteins begun to be described. A 90,000-dalton nonstructural PRV glycoprotein secreted into the medium of infected cells was reported to be encoded by the Us region of the PRV genome (25) . Similarly, the tentative locations in the Us region of genes encoding PRV glycoproteins of 130,000 and 50,000 daltons have been described (22, 31 (27) .
We now report the further characterization of this PRV glycoprotein gene found in the UL region. Previously, we described two different expression plasmids, designated pDPR7 and pDPR123, carrying adjacent but nonoverlapping PRV DNA segments that specified PRV--galactosidase fusion proteins. Antisera produced in rabbits against either fusion protein immunoprecipitated the same two, apparently related, PRV-encoded glycoproteins of 92,000 and 74,000 apparent molecular weight. Our hypothesis was that the PRV DNA segments cloned in either expression plasmid represented different regions of the same gene. In this report, we confirm this hypothesis and describe the detailed mapping, mRNA characterization, and complete nucleotide sequence of this PRV glycoprotein gene.
MATERIALS AND METHODS
Animal cells and virus. The swine kidney cell line PK15 and the Becker strain of PRV have been described previously (27 (kb) PRV SphI-BamHI fragment replacing the SphI-BamHI fragment of pBR322. Plasmid pK64 contains the PRV KpnI J fragment cloned into the KpnI site of polink26. Plasmid p7-123AM is described in detail below.
Construction of expression plasmid p7-123AM. The basic expression vector, ptc412, is derived from pJS413 (27) . In this vector, the first 23 amino acids of the bacteriophage lambda cro gene are used as a "leader" for efficient translation. The p7-123AM is designed to express either the Cro-PRV fusion protein alone or both Cro-PRV and Cro-PRV-,Bgalactosidase fusion proteins concomitantly. This is accomplished by the insertion of a synthetic DNA sequence containing an amber nonsense codon at the PRV-lacZ DNA junction (see Fig. 5 ). When such a plasmid is carried by a wild-type cell, translation terminates at the nonsense codon, resulting in the production of only the Cro-PRV fusion protein. However, when the plasmid is carried by a cell with a nonsense suppressor mutation, the nonsense codon is translated, and the entire Cro-PRV-3-galactosidase fusion protein is made. In addition, however, the Cro-PRV fusion protein is also produced because suppression of the nonsense codon is less than 100% efficient. This concomitant production of both fusion proteins has proven to be of value for isolation of the Cro-PRV fusion protein since it will coaggregate with the Cro-PRV-,-galactosidase protein in large intracellular inclusions, simplifying purification (36) . In the case of p7-123AM, concomitant expression of both fusion proteins was not necessary to stabilize the Cro-PRV fusion protein, presumably because the Cro-PRV fusion protein itself forms insoluble aggregates.
The construction of p7-123AM was accomplished in two steps. First a Cro-PRV-p-galactosidase protein fusion was made; second, a DNA linker containing an in-frame nonsense codon was inserted at the PRV-lacZ junction. A 2.5-kb SphI-BamHI fragment of PRV genomic DNA (located from 0.0 to 2.5 kb in Fig. 1C ) was cloned in pBR322. This plasmid, designated p7-123, carries the PRV gene of interest. p7-123 DNA was digested with NcoI, and the cohesive ends were filled in by using the Klenow fragment of DNA polymerase I and all four deoxyribonucleotides. The DNA was then digested with BamHI, and a PRV DNA fragment containing 1,380 bp of the putative PRV glycoprotein-coding sequence was isolated. By DNA sequence analysis (see Fig. 4 ), this fragment contains the coding sequence from amino acid 1 Fig. 5 ). Immunological analysis of the fusion protein produced by p7-123AM is described in Results.
Production and isolation of Cro-PRV fusion proteins from E. coli. The production and isolation methods were essentially those described by Watson et al. (36) . The Cro-PRV fusion protein specified by p7-123AM was produced at approximately 3% of total cellular E. coli protein as determined by Coomassie brilliant blue staining of sodium dodecyl sulfate-polyacrylamide gels (see Fig. 6 ).
Northern blot analysis of PRV RNA. Total cytoplasmic RNA was extracted from uninfected or PRV-infected cells at various time points as described previously (33) and fractionated by electrophoresis on a 1% agarose gel containing 2 M formaldehyde-0.02 M morpholinepropanesulfonic acid-5 mM sodium acetate-1 mM EDTA, pH 7 (20) . The RNA was subsequently transferred to a nitrocellulose membrane (30) and hybridized at 42°C for 16 h with DNA probes labeled with 32P by nick translation (26) . The hybridization solution contained 50% formamide, 1 M sodium chloride, 50 mM sodium phosphate, 5 Sl nuclease and ExoVII analysis of RNA. The protocols of Berk and Sharp (2) were followed by using 5' or 3' endlabeled fragments as probes (Fig. 1D , E, and F). Probes were labeled at their 5' or 3' ends as described previously (3) .
DNA sequencing. The method of Maxam and Gilbert (21) was used for DNA sequence analysis.
Preparation of cell extracts and immunoprecipitations. The techniques for making cell extracts for immunological analysis were described previously (27) .
Preparation of Cro-PRV fusion proteins expressed in E.
coli. E. coli cells containing the plasmid p7-123AM were grown overnight at 37°C with shaking in L-broth containing 100 ,ug of ampicillin per ml. The cells were subsequently diluted 1:50 in similar fresh medium and shaken for 4 h at 37°C. The expression of the Cro-PRV fusion protein was induced by adding isopropyl-,-D-thiogalactopyranoside (IPTG) to 1 mM final concentration. At Plasmid p7-123 carries the SphI-BamHI fragment as preeach probe is indicated by an viously described. The 1.6-kb XhoI fragment that contains the DNA carried by both pDPR7 and pDPR123 was labeled at the 5' or 3' end as described previously (34) . The 5' or 3' frozen at -70°C. The Cro-PRV fusion protein is produced as an insoluble aggregate or inclusion body. Purification of the aggregated protein was done essentially as described by Watson et al. (36) .
Production of rabbit antisera. A sample of Cro-PRV fusion protein suspension was adjusted to 50 mM NaOH and incubated at 60°C for 10 min. The suspension was then neutralized with 1 M hydrochloric acid and then emulsified with complete Freund adjuvant. Approximately 250 ,ug of emulsified fusion protein was injected intramuscularly into New Zealand White rabbits. Three weeks after the first injection, the rabbits were given booster injections with 250 ,ug of protein in incomplete Freund adjuvant. One week after the second injection, the rabbits were bled from the marginal ear vein, and the antisera were used for immunological studies.
RESULTS
Previously, we had suggested that the PRV DNA sequences represented in pDPR7 and pDPR123 were likely to come from a single PRV glycoprotein gene located in the UL region (27 (Fig. 3) indicated that a 1.4-kb fragment was protected with the 2.5-kb SphI-BamHI probe and a 0.95-kb fragment was protected with the 2.1-kb SphISmaI probe. From these results, we conclude that the 5' end of the RNA is situated 1.4 kb from the BamHI site and 0.95 kb from the SmaI site close to the NcoI site at 1.1 kb (Fig. 1) . The sizes of the protected fragments when ExoVII was used to digest the RNA-DNA hybrids were identical to those seen for Si digestion (Fig. 3) . Such results are consistent with the absence of intervening sequences in this RNA.
A more precise location of the 3' end was done as follows. Plasmid pK64 carries the 5.7-kb PRV KpnI J fragment that overlaps the PRV BamHI 2 fragment, which, based on the previous data (27) , should encode the 3' terminus of the transcript. Plasmid pK64 was cleaved with XhoI, and the 3' termini were labeled with 32P as described previously (34) . The labeled DNA was subsequently digested with NcoI to yield an XhoI-NcoI fragment of 1.1 kb (Fig. 1F) . This fragment was then hybridized to total cytoplasmic RNA from PRV-infected cells as described previously (34) . RNA-DNA hybrids were digested with S1 or ExoVII and analyzed as previously described. A 0.2-kb fragment was protected from either S1 or ExoVII nuclease digestion (data not shown). This establishes the location of the transcript's 3' end at 0.2 kb from the XhoI site (Fig. 1C) . In addition, these experiments further indicate that the transcript is not spliced. Preliminary S1 nuclease protection experiments indicate that the 5' mRNA terminus is somewhat heterogenous and located between positions 180 and 189 (Fig. 4) (data not shown).
DNA sequence analysis. The entire nucleotide sequence (both strands) of the region was determined (Fig. 4) . A single open reading frame of 1,437 bp was found that contained both the sequences cloned in pDPR7 (bases 413 through 907) and pDPR123 (bases 1127 through 1489) as well as those sequences defined by RNA-DNA hybridization (Fig. 3) . The overall base composition of the open reading frame was 11.2% A, 13.6% T, 34.3% G, and 40.9% C. The codon usage for the 479 amino acids is given in Table 1 . Given the high G+C content, it perhaps is not surprising that codon bias exists. For example, 23 codons are not used at all. It is remarkable that more than one-third of the amino acid content is composed of only three amino acids: valine (11.3%), alanine (14.4%), and proline (9.2%).
The DNA sequence for 196 bp upstream and 90 bp downstream of the coding sequence was determined (Fig. 4) . The base composition of these regions was not markedly different from that of the open reading frame. The TATA box with the consensus sequence of 5'-TATAA/TAA/T-3' is usually found 26 to 34 bp upstream of the site of initiation of transcription in higher eucaryotes (8) . The sequence TTTT TAAAA (residues 151 through 159) may represent the TATA sequence for this gene. In addition, the sequence GCATTAAA (residues 111 through 118) may be analogous to the CAT box motif characteristic of many eucaryotic promoters (4, 8) . The initiation codon of the gene is likely the ATG at residue 196. It is the first ATG in the transcript and is followed by an open reading frame of 478 codons. We note that there is a subsequent ATG codon in the same reading frame (residue 217). It has been predicted that efficient translation initiation in eucaryotes depends on a purine residue, usually an A, at position -3 relative to the initiating ATG codon (15) . The -3 position of either ATG (position 196 or 217) is a G. Downstream of the ATG, a purine at position +4 (16) has been implicated in playing a role in the efficiency of translation. By this argument, the first ATG would be more efficient (+4 = G) than the second (+4 = C).
The proposed stop codon, TGA, is found at nucleotide 1,633. A potential polyadenylation signal, AATAAA The predicted amino acid sequence for the polypeptide encoded by this gene is also indicated in Fig. 4 . The molecular weight of the primary translation product would be 50,860. The protein predicted from the DNA sequence has features in common with envelope glycoproteins from other herpesviruses (5, 11, 12, 24, 29, 32, 35 Doolittle (17) and the empirically based secondary structure analysis of Gamier et al. (13 galactosidase fusion proteins from the expression plasmids pDPR7 and pDPR123. We had demonstrated that antisera made against either of these fusion proteins immunoprecipitated similar glucosamine-labeled PRV proteins of 92,000 and 74,000 apparent molecular weight. The problem with these antisera was that they only reacted with denatured protein; they did not react with native material. In addition, major portions of the protein, particularly the aminoterminal segments, were not represented in either fusion protein. A further complication was that the majority of the mass of each fusion protein was ,-galactosidase. These shortcomings were eliminated as follows. By knowing the complete DNA sequence, we were able to express better than 96% of the open reading frame in E. coli as a Cro-PRV protein unfused to 3-galactosidase as described by Watson et al. (36) and in Materials and Methods.
This plasmid, p7-123AM, is diagrammed in Fig. 5 . The construction of this plasmid is described in Materials and Methods. The hybrid trp-lac or tac promoter used was regulated by the lac repressor, and IPTG was used as the inducer. Upon induction in the suppressor-negative host, NF1829, p7-123AM directs the production of only the Cro-PRV fusion protein (Fig. 6) . The Cro-PRV fusion protein is produced in significant quantities and is found in large, insoluble aggregates. Purification of the Cro-PRV fusion protein is easily done by collecting the aggregates by centrifugation as described in Materials and Methods.
The physiology of E. coli carrying p7-123AM was markedly affected upon IPTG induction. Cell division rapidly stopped, although the Cro-PRV fusion protein continued to accumulate. The phenomenon was observed in both suppressor-positive and -negative strains. We have not investigated this phenomenon further to date, although similar phenomena have been observed previously (36) .
Analysis of antisera directed toward the Cro-PRV fusion protein. The Cro-PRV fusion protein was partially purified from a culture of E. coli carrying the plasmid p7-123AM as described in Materials and Methods. The fusion protein was then injected into rabbits to raise antibodies as detailed in Materials and Methods. Extracts prepared from [3H]glucosamine-labeled PRV-infected cells were reacted with anti-PRV serum as a control or antisera raised in rabbits against the Cro-PRV fusion protein. The anti-PRV serum specifically immunoprecipitated PRV glycoproteins of 110,000, 92,000, 74,000, and 55,000 apparent molecular weight as described previously (27) . Rabbit (-) or induced (+) were harvested at 1 h, 2h, and 4 h and after overnight (O/N) incubation with inducer. The Cro-PRV fusion proteins were found in insoluble aggregates and were prepared as previously described (36) . The aggregated proteins were fractionated by electrophoresis on a 10% polyacrylamide-sodium dodecyl sulfate gel followed by staining with Coomassie blue. The position of the Cro-PRV fusion protein is indicated by the arrow. The locations of molecular weight standards are indicated (x 1,000). A similar precursor-product relationship has been observed with herpes simplex virus type 1 glycoprotein C (7). We have observed that the 74,000-molecular-weight protein does not appear to be present in purified virions (data not shown). A test of this hypothesis will come from experiments that inhibit glycosylation in vivo, from in vitro translation of specific mRNA, or from removal of the sugar modifications by enzymatic treatment of purified proteins.
DISCUSSION
In this paper we expand our initial observations in which we located a PRV glycoprotein gene within the PRV genome (27) . Since the two expression plasmids used to localize the new PRV gene carried different DNA segments that did not overlap, it was important to prove directly that they carried DNA from the same PRV gene. We have proven this unequivocally by DNA sequence analysis, mRNA analysis, and immunological studies of bacterially produced fusion proteins.
This PRV glycoprotein gene is defined by an open reading frame of 1,437 bases or 479 codons. The 1.55-kb mRNA transcript of this sequence is not spliced. The transcript was observed as early as 4 h postinfection and seemed to be present at increased levels at 8 h postinfection. Since the 4-h time point was the earliest examined, it may well be that the transcript is synthesized earlier in the cycle.
Analysis of the primary sequence and the predicted amino acid sequence indicates that the protein has a structure with some features in common with most herpesvirus glycoproteins. There is a hydrophobic sequence of about 22 amino Protein similarity between herpes simplex virus type 1 glycoprotein C and the PRV glycoprotein glll. Shown to the left is a dot matrix study with the deduced amino acid sequence of herpes simplex virus type 1 glycoprotein C (13, 29) on the Y-axis and the deduced amino acid sequence of PRV gIII on the X-axis. The method was described previously (19) . The window was 30 and the stringency was set at 8. Shown to the right is the printout from an FASTP homology search of the Dayhoff protein sequence library by the method of Lipman and Pearson (18) . The ktup value was set at 1 for this search. The PRV glll amino acid sequence in single-letter code begins on the first line and is numbered on the left as 1'. In a similar fashion, the herpes simplex virus type 1 glycoprotein C amino acid sequence begins on the second line and is numbered on the left as 1". Identical amino acids (:), similar amino acids (.), and gaps introduced by the alignment algorithm (--) Computer analysis revealed no significant DNA homology to the known DNA sequences of other herpesvirus glycoproteins (data not shown). Homology at the amino acid level was also very minimal with the exception of glycoprotein C from herpes simplex virus type 1 and type 2. The homology presented in Fig. 8 was detected by using the FASTP homology search program of Lipman and Pearson (18) , scanning the Dayhoff protein data base. For herpes simplex virus type 1 glycoprotein C, the 22.3% homology extends over 466 amino acids. The majority of matches are for similar, but not identical, amino acids. The similarity was significant as judged by a Monte Carlo shuffle test with the RDF program of Lipman and Pearson (18) . The dot matrix homology analysis of Maizel and Lenk (19) also provided evidence of similarity (Fig. 8) . The herpes simplex virus type 2 glycoprotein C gene (29) exhibited similar homology patterns (19.0% homology over 458 amino acids; data not shown). Although it may be that the PRV and herpes simplex virus proteins have evolved portions of a common primary protein structure, there is no evidence for immunological cross-reaction (unpublished observations). Further work is necessary to determine whether these proteins share any common functions and indeed are analogs.
Hampl et al. (14) used monoclonal antibodies to define specific PRV glycoproteins. The nomenclature proposed would number them with roman numerals gI, gll, glll, gIV, and gV. We have attempted to use these reagents to define more precisely this new glycoprotein. Unfortunately these monoclonal antibodies did not react with the protein expressed in E. coli, presumably because they recognize conformational determinants not present in the bacterial product. However, using recombinant DNA techniques we have introduced defined mutations into the gene identified in this paper and have demonstrated appropriately altered glycoproteins that react with gIll-specific monoclonal antibodies (A. K. Robbins 
